Natural Capsules Limited — PPTs, 13-08-2026: Investor Presentation

Natural Capsules Ltd. reported Q1FY27 revenue of ₹48.71 Cr, up 8% YoY, with EBITDA at ₹1.12 Cr, a 251% YoY jump. PAT was (₹5.74 Cr), up 3% YoY, and EPS stood at (₹5.55), also up 3% YoY. The capsules business delivered a strong quarter with sustained demand and improved realizations, especially in gelatine, despite an ERP rollout pushing some sales to Q2. However, erratic US demand led to HPMC lines being converted to gelatine production. The API business faced geopolitical and currency headwinds.

Strategically, the company is enhancing capsule capacity and aims to lead the domestic steroidal API market as a backward-integrated player, focusing on regulated markets for capsules. Recent progress includes starting contract manufacturing with Fermbox Bio, securing a new client, successful prednisolone synthesis, and improving fermentation yields. A new COO has been appointed for the API business. Management is focused on scaling API volumes, maintaining capsule profitability, and achieving crucial compliance milestones for future growth.